Adalimumab refers to adalimumab, sacroiliac arthritis with adalimumab can effectively control disease activity, improve clinical symptoms, but generally can not be completely cured. Sacroiliac arthritis is not a single class of disease, divided into primary and secondary sacroiliac arthritis. Primary sacroiliac arthritis is a sterile inflammation of the sacroiliac joints, mainly manifested as pain. It is a chronic disease that is generally incurable and can only be treated to relieve discomfort. Secondary sacroiliac arthritis is often secondary to ankylosing spondylitis, femoral head lesions, medical factors, damage to the hip joint or crystalline lesions, endocrine disorders and metabolic dysfunction, hip tuberculosis, etc., and the above lesions can not be completely cured. And adalimumab can effectively control sacroiliac arthritis, ankylosing spondylitis and other disease activity, improve the patient’s physical function and quality of life. However, it does not cure the disease. Adalimumab is currently described as a biologic palliative anti-rheumatic drug. It can generally be used in patients with high disease activity, a combination of poor prognostic factors, and failure of NSAID therapy, but should be contraindicated in patients with hypersensitivity to the product or other components of the formulation, active tuberculosis or other serious infectious disorders such as sepsis and opportunistic infections, and moderate to severe heart failure. The overall safety profile of adalimumab is favorable, with the most common adverse reactions being infusion or injection site reactions. Other adverse reactions include an increased chance of infection, particularly an increased risk of tuberculosis infection, and routine screening for tuberculosis prior to treatment, and the use of the drug is subject to medical advice.